Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30216977 | 0.88 | SIRT2 (0.43) | CYP4F2CYP4A11TDP1ALDH1A1 | |
| SCHEMBL4425984 | 0.78 | CYP4F2 (0.64) | CYP4F2CYP4A11CYP4Z1TDP1PPARA | |
| SCHEMBL1124698 | 0.76 | CYP4F2 (0.54) | CYP4F2CYP4A11CYP4Z1TDP1PPARA | |
| SCHEMBL5666289 | 0.75 | NAAA (0.47) | CYP4F2CYP4A11TDP1PPARAPPARG | |
| SCHEMBL10504954 | 0.74 | CYP4F2 (0.55) | CYP4F2CYP4A11CYP4Z1TDP1PPARA | |
| SCHEMBL13104077 | 0.74 | CYP4F2 (0.58) | CYP4F2CYP4A11TSHRCYP4Z1TDP1 | |
| SCHEMBL879289 | 0.74 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1TDP1PPARA | |
| SCHEMBL10725552 | 0.73 | CYP4F2 (0.61) | CYP4F2CYP4A11CYP4Z1TDP1PPARA | |
| SCHEMBL22070553 | 0.73 | CYP4F2 (0.76) | CYP4F2CYP4A11CYP4Z1TDP1PPARA | |
| SCHEMBL2745464 | 0.73 | CYP4F2 (0.57) | CYP4F2CYP4A11TDP1PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | SIONNA THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023034992-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | CYP4F2 1768/4885CYP4A11 966/4885TSHR 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.